Dr. P. Mortele - I. De Schryver

Niraparib Maintenance Therapy Extends Quality-Adjusted Survival by 8 Months in Advanced Ovarian Cancer

- Niraparib significantly improved quality-adjusted progression-free survival by approximately 8 months compared to placebo in women with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. - The PRIMA trial demonstrated that niraparib extended quality-adjusted time without symptoms of disease or toxicity by 9 months in the overall cohort, with even greater benefits observed in patients with homologous-recombination-deficient tumors. - Disease progression was associated with marked deterioration in health-related quality of life across multiple functional scales, supporting progression-free survival as a clinically relevant endpoint in advanced ovarian cancer treatment.